Global health: Epidemics and communicable diseases
We have comprehensive knowledge and expertise in communicable diseases (HIV/AIDS, malaria, TB, viral hepatitis); pandemic and epidemic diseases (COVID-19, influenza and cholera) and non-communicable diseases.
CEPA has extensive knowledge and expertise on epidemic and communicable diseases through our work with the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Fund, the World Health Organization (WHO), UNAIDS, Unitaid, the Stop TB Partnership, the Roll Back Malaria Partnership to End Malaria, the Malaria Consortium and other organisations.
Within epidemics, we have recently completed an independent evaluation for CEPI to assess CEPI 1.0 in terms of its effects on society (i.e., the impact of CEPI’s activities and investments), the sustainability of the results achieved, and the main lessons learned from CEPI’s first five years. The review sought to assess performance and results under CEPI 1.0 to inform its next strategy for CEPI 2.0. We also completed a large-scale portfolio-level evaluation assessing the contribution of Unitaid’s COVID-19 response between March 2020 to October 2021, and alignment with the ACT-A partnership.
We have worked in a range of areas within communicable diseases. This includes extensive work in HIV/AIDS where, for example, we conducted a thematic review of the Global Fund’s investments in HIV primary prevention, we reviewed Unitaid’s portfolio of support for HIV self-testing and their portfolio of support for HIV molecular diagnostics. We have also worked in the area of integration of HIV and TB, including our evaluation for the Unitaid grant to Médecins Sans Frontières (MSF) on viral load monitoring, which included reviewing the demand for multi-platforms for diagnosis of HIV/TB co-infections as well as our evaluation of the Unitaid’s Medicines Patent Pool – an independent Foundation with the objective of providing patients in LMICs with increased access to health products through a voluntary patent pool mechanism, which included a review of expanding the remit of the foundation to diseases such as TB.
We have undertaken a number of projects within the malaria space spanning prevention, diagnosis and treatment. For example, we undertook the end of project evaluation of the Unitaid Next Generation Indoor Residual Spray (NgenIRS) project which aimed to introduce third-generation Indoor Residual Spraying (3GIRS) products, as well as both the mid and end of project evaluations for Unitaid of the Improving Severe Malaria Outcomes (ISMO) project. CEPA’s malaria experience is complemented by other evaluation work for the Global Fund, support to the Medicines for Malaria Venture (MMV) on their impact measurement methodology and the development of funding approaches for malaria for malaria-eliminating countries with the Malaria Elimination Initiative at the University of California San Francisco.
CEPA has undertaken a range of work within TB including a value for money assessment of the Stop TB Partnership; an evaluation of the Global Fund’s Cooperation Agreements with WHO and the Stop TB Partnership on the provision of technical assistance to support the development of country concept notes and grant-making; and an evaluation of Unitaid’s funding for the introduction and scale-up of the GeneXpert technology for TB diagnosis.
On other epidemics, some other examples of our work include developing an economic case for dengue investment in Myanmar based on a synthesis of available data on the disease and economic burden. We have also worked on cholera through our support to the Global Task Force for Cholera Control (GTFCC) at the WHO, where we sought to assess its functions and performance and areas for further work in cholera in the future.
Within communicable diseases, we have undertaken a number of projects to measure impact for our clients, with further information being found here.
Epidemics and communicable diseases
We have comprehensive knowledge and expertise in communicable diseases (HIV/AIDS, malaria,...
Health & community systems strengthening
Our team has substantial experience in the design, implementation and evaluation of...
Our team has extensive experience in immunisation systems strengthening and knowledge of...
We use quantitative modelling to help global health organisations understand the difference...
Market dynamics, supply & access
CEPA has substantive experience in retrospective and prospective market dynamics analyses, including...
Sexual, reproductive, maternal, newborn, child & adolescent health
We have a strong understanding of the priorities and issues on the...
Universal health coverage
CEPA’s work supports organisations and governments in moving towards UHC...
Global health News & insights
CEPA supports water, regulatory finance and global health practices with promotions to its partnership
Join us in congratulating Tom Cochrane and Kaveri Kumar on their recent promotions to the firm’s partnership. They join CEPA’s existing global Partners to lead a growing team of more than 50 economic, public and financial policy consulting experts.
Reputation acknowledged by ranking recognition
CEPA thanks those clients, industry leaders, associates and future economists for the feedback they provided to Consultancy.uk, resulting in the firm’s high-level, 2023 ranking as one of the “Top Economics consulting firms in the UK”.
LSE students present findings about biodiversity policy
We are pleased to have supported another cohort of students undertaking the Capstone Course at the London School of Economics (LSE).
CEPA has again been recognised as one of the UK’s leading management consultants
We are grateful for the continued positive feedback from the market, which has led to CEPA retaining its position in the Financial Times' ratings.
CEPA evaluates Unitaid’s $22m investment aimed at supporting access to medicines
Our Global Health team's evaluation of Unitaid's portfolio to 'support access to medicines through innovative use of Trade Related Aspects of Intellectual Property Rights' has been published.
Our report on “Accelerating the Equitable Deployment and Access to Innovations” is published by the Global Fund
A technical evaluation by CEPA's Global Health team, to assess how the Global Fund is performing in terms of supporting innovations.
CEPA’s independent outcome evaluation of CEPI is published
Dr Richard Hatchett, the Chief Executive Officer of The Coalition for Epidemic Preparedness Innovations praises our work, describing it as “a fair, balanced and independent perspective”.
Operational review of Global Fund supported HIV prevention programs for Adolescent Girls and Young Women
CEPA was commissioned by the Global Fund to fight AIDS, Tuberculosis and Malaria (the Global Fund) to conduct an operational review of Global Fund-supported HIV prevention programs for AGYW across 13 priority countries in sub-Saharan Africa.
Unitaid publishes CEPA’s reports on HIV Self-Testing and Covid-19
Our external evaluations are considered to be an essential component of Unitaid's approach to grant management and monitoring, transparency and accountability, and communicating impact and learning.
Independent Outcome Evaluation for The Coalition for Epidemic Preparedness Innovations
Our global health team's Independent Outcome Evaluation has been published by The Coalition for Epidemic Preparedness Innovations (CEPI).
The potential impact of future innovation in support of Unitaid’s strategy
We explored the potential impact of ten promising innovations that Unitaid may support during its 2023-27 strategic period, which could make a significant contribution to advancing global health targets.
Evaluation of Unitaid’s COVID-19 portfolio of investments
CEPA was appointed by Unitaid to undertake a portfolio-level evaluation assessing the contribution of Unitaid’s COVID-19 response and alignment with the ACT-A partnership.
Evaluation of the UNAIDS contribution to Efficient and Sustainable Financing
CEPA was appointed by the UNAIDS Independent Evaluation Office to lead an evaluation of the Joint Programme’s work on equitable, efficient and sustainable financing for the HIV response.
Unitaid HIV self-testing evaluation
End of project evaluation of Unitaid’s HIV Self-testing (HIVST) portfolio.
CEPA recognised as one of the UK’s leading management consultants
Following another year of providing high-quality advice to our clients across our core sectors, we are grateful for the positive feedback from the market, which has led to CEPA’s inclusion in the Financial Times’ independent ratings report.
Modelling the impact of a patent pool for essential medicines in low- and middle-income countries
The Medicines Patent Pool (MPP) is a Geneva-based organisation that negotiates and manages licences for essential medicines, which it makes available to generic manufacturers for the benefit of low- and lower-income countries.
CEPA evaluates Unitaid’s investments in Hepatitis C
Unitaid has invested more than US$45 million since 2015 in support of improving access to care for hepatitis C. We are pleased to have provided them with a portfolio evaluation and end of grant evaluations.
Unitaid molecular diagnostics portfolio review
CEPA was appointed by Unitaid to conduct a portfolio-level joint end-of-grant evaluation of its investments in Point of Care (POC) molecular diagnostics for HIV.
Evaluation of the Partnership for Maternal, Newborn and Child Health (PMNCH)
CEPA was commissioned by the PMNCH Board to conduct an external evaluation of PMNCH. The evaluation was of strategic importance in the context of developing the next Strategic Plan for PMNCH for the period 2021-2025.
Gavi supply and procurement strategy evaluation
CEPA was appointed by Gavi to conduct an evaluation of the 2016-20 Supply and Procurement Strategy (their market shaping strategy). This large-scale evaluation involved an assessment of the design, implementation and results of the strategy.
TERG / Global Fund HIV primary prevention review
The Global Fund Technical Evaluation Reference Group (TERG) commissioned CEPA to conduct a review of the Global Fund’s investments in HIV primary prevention.
Evaluation of Unitaid Next Generation Indoor Residual Spray (NgenIRS) project
Unitaid commissioned CEPA to conduct an end of project evaluation of the NgenIRS project which aimed to facilitate the creation of a sustainable market for third-generation Indoor Residual Spraying (3GIRS) products.
Unitaid long-acting HIV drugs modelling support
Unitaid commissioned CEPA to develop a model to quantify the potential uptake and impact of long-acting drugs for anti-retroviral treatment of HIV.
Gavi eligibility and transition and co-financing policy evaluation
Evaluation of Gavi’s Eligibility and Transition and Co-financing Policies.
Power of Nutrition Results Framework
CEPA was engaged to evaluate CEPI's results management system. This focused on assessing whether the approach to monitoring and reporting results was relevant, meeting the needs of its donors.
Applying the ‘no-one worse off’ criterion
Laura Grobicki has contributed to an article published in the journal 'AIDS', related to the HIV allocative efficiency modelling work she undertook in Togo.
Evaluation of cooperation agreements between health organisations
The Global Fund commissioned CEPA to conduct an evaluation of its Cooperation Agreements with WHO and the Stop TB Partnership on the provision of technical assistance to support the development of country concept notes and grant-making.
Thematic review to assess an approach to investing in resilient & sustainable systems for health
CEPA conducted a thematic review to assess the Global Fund’s current approach to investments in Resilient and Sustainable Systems for Health (RSSH).
Evaluation of community, human rights and gender interventions
CEPA was appointed to develop an evaluation framework and methodology to help the Stop TB Partnership to evaluate its community, human rights and gender focused work.
Monitoring of Gavi Market Shaping Externalities
As part of its Supply and Procurement Strategy for 2016-2020, Gavi committed to monitor any negative and positive unintended consequences, so-called externalities, that could arise from its market shaping activity.
Evaluation of Gavi health system strengthening support to Nepal
Gavi commissioned an evaluation of its Health System Strengthening (HSS) support to Nepal through the pooled funding mechanism.
Modelling ROI on reproductive, maternal, newborn, child & adolescent health & nutrition interventions
CEPA conducted a modelling of the Global Financing Facility’s return on investment for Reproductive, Maternal, Newborn, Child and Adolescent Health and Nutrition (RMNCAH-N) interventions.
Making markets for children with HIV
Our evaluation of the impact of Unitaid's support for treating children living with HIV demonstrated the pivotal role the organisation had in creating a market for paediatric antiretroviral (ARV) medicine.
Framework for integration of disease programmes into health systems
CEPA was commissioned by the Global Fund to develop a framework and diagnostic tool for assessing governance-level bottlenecks to the integration of disease programmes into national health systems.
Mid-term evaluation of the Unitaid “Self-testing Africa (STAR)” project
CEPA was appointed to review the implementation of the first phase of Unitaid’s HIV self-testing grant to identify areas that worked well and those that worked less well, determine the extent to which the project achieved its intended impacts.
Advisory support to the Partnership for Maternal, Newborn and Child Health
CEPA was asked to carry out an analysis of the factors affecting provision of Overseas Development Assistance (ODA) for Sexual, Reproductive, Maternal, Newborn, Child and Adolescent related health programmes (SRMNCAH).
Review of the Global Task Force on Cholera Control
CEPA was appointed by the Global Task Force on Cholera Control (GTFCC) to conduct an independent review of the revitalised Task Force.
Evaluation of the ‘Improving Severe Malaria Outcomes’ project
CEPA was appointed to conduct a mid-term and an end-term review of Unitaid’s “Improving Severe Malaria Outcomes” project.
Development of Global Strategy for Womens’, Childrens’ & Adolescents’ Health
CEPA supported the PMNCH’s Consultation on the Global Financing Facility in conducting a global consultation process and producing a report.
Gavi’s new country engagement framework
CEPA was appointed by Gavi to capture feedback and document lessons during the early implementation phase of Gavi’s new country engagement framework approach.
Development of Gavi application guidelines
CEPA was commissioned to develop Gavi’s Application Guidelines and Forms for 2016 and 2017.
Health systems strengthening country evaluations
CEPA conducted a meta-review of 14 country evaluations of Gavi HSS support in order to inform Gavi’s review of its HSS window of support.
Prospective evaluation design for the Bangladesh Home Fortification Project
CEPA supported CIF with an evaluation of the Bangladesh Home Fortification Project, aimed at reducing anaemia among young children.
Evaluation of the Stop TB Partnership
CEPA was appointed to undertake a Value for Money (VfM) evaluation of the Stop TB Partnership covering the period 2007 to 2013.
Innovative financing mechanisms for malaria elimination
CEPA was appointed to review current financing trends for malaria eliminating countries and consider suitable innovative financing mechanisms that could be developed to support malaria elimination.
Review of Unitaid’s Medicines Patent Pool (MPP)
CEPA undertook a review to closely assess the strategic direction, positioning and operations of the MPP.
Evaluation of the Norway India Partnership Initiative
CEPA was appointed by the Evaluation Department at Norad to conduct a process evaluation of the Norway India Partnership Initiative (NIPI) with the aim to reduce child and maternal mortality.
Investment case for Civil Registration and Vital Statistics
The purpose of the assignment was to prepare an investment case for Civil Registration and Vital Statistics (CRVS) systems, to serve as a key advocacy document to garner support for and investment in, CRVS systems.
Mid-term review of GAIN’s Infant and Young Child Nutrition programme
CEPA conducted a mid-term review of GAIN’s Infant and Young Child Nutrition programme.
Evaluation of Gavi Phase II
A consortium led by CEPA carried out the second evaluation of Gavi. The evaluation assessed Gavi’s performance since inception, focusing on the period between 2006 and 2009.